March 22 (Reuters) - The European medicines regulator on Monday advised against the use of Merck & Co’s anti-parasite drug, ivermectin, for the treatment or prevention of COVID-19 outside clinical trials.
The advice from the European Medicines Agency (EMA) comes more than a month after Merck warned against the use of the drug to treat COVID-19 as its analysis of available data did not support the safety and efficacy of the drug. (Reporting by Yadarisa Shabong in Bengaluru; Editing by Shailesh Kuber)
我们的标准: 汤森路透“信任原则”